Hormonal therapies for ERα-positive (ER+) BC target ERα either directly, by selective ER modulators and down-regulators, or indirectly, by abolishing estrogen production by inhibitors of aromatase, the rate-limiting enzyme in estrogen biosynthesis. This evidence concerns the gene CYP19A1 and breast cancer.